Patient flow through SDAI categories during the DE period
REMISSION
Of the 56 patients from the abatacept + MTX arm who achieved early (at week 24) sustained SDAI remission during the IP, SDAI status was unknown for four patients during the DE period of the study (data not shown). For the remaining patients who achieved early sustained SDAI remission, the flow of the population through SDAI categories during the DE period is shown in Fig. DE-period SDAI categories in patients achieving sustained SDAI remission earlyAmong patients who achieved early sustained remission, a higher proportion who were re-randomized to continue abatacept QW + MTX (82% [14/17]) or receive abatacept monotherapy (81% [13/16]) at week 56 were in remission at the end of the DE phase (DE week 48) compared with patients who were re-randomized to de-escalate to abatacept EOW + MTX for 24 weeks and then stop abatacept treatment (63% [12/19]) (Fig. 